Showing 3,481 - 3,500 results of 18,313 for search 'significantly ((a decrease) OR (((((teer decrease) OR (greatest decrease))) OR (mean decrease))))', query time: 0.70s Refine Results
  1. 3481

    Table 2_CHMP4A in hepatocellular carcinoma: exploring its role in tumor progression, immune modulation, and potential link to TIM3 checkpoint.docx by Kai Sun (140584)

    Published 2025
    “…Background<p>Charged Multivesicular Body Protein 4A (CHMP4A), a member of the ESCRT-III family, plays a pivotal role in membrane remodeling and fission, with emerging evidence underscoring its significance in cancer immunotherapy. …”
  2. 3482

    Image 2_CHMP4A in hepatocellular carcinoma: exploring its role in tumor progression, immune modulation, and potential link to TIM3 checkpoint.pdf by Kai Sun (140584)

    Published 2025
    “…Background<p>Charged Multivesicular Body Protein 4A (CHMP4A), a member of the ESCRT-III family, plays a pivotal role in membrane remodeling and fission, with emerging evidence underscoring its significance in cancer immunotherapy. …”
  3. 3483

    Data Sheet 1_CHMP4A in hepatocellular carcinoma: exploring its role in tumor progression, immune modulation, and potential link to TIM3 checkpoint.docx by Kai Sun (140584)

    Published 2025
    “…Background<p>Charged Multivesicular Body Protein 4A (CHMP4A), a member of the ESCRT-III family, plays a pivotal role in membrane remodeling and fission, with emerging evidence underscoring its significance in cancer immunotherapy. …”
  4. 3484

    Table 1_Eculizumab is efficacious and safe in pediatric patients with various forms of hemolytic uremic syndrome: a retrospective clinical experience of a tertiary center.docx by Naama Lax (20998004)

    Published 2025
    “…TMA event-free status was reached in 15 (63%) patients. Significant improvements were observed in platelet count (63%), lactate dehydrogenase levels (76% within the first week), hemoglobin (60%), and estimated glomerular filtration rate (79%); while CH-50 levels decreased. …”
  5. 3485

    Data Sheet 1_Genetic knockdown of DYRK1A attenuates cognitive impairment, Aβ pathology, tauopathy and neuroinflammatory responses in mouse models of AD.docx by Hyun-ju Lee (7550741)

    Published 2025
    “…Conversely, in amyloid-beta (Aβ)-overexpressing 5xFAD mice, hippocampal DYRK1A knockdown improved short-term spatial/recognition memory and significantly increased CaMKIIα and CREB phosphorylation. …”
  6. 3486
  7. 3487

    Data Sheet 2_A novel molecule targeting neutrophil-mediated B-1a cell trogocytosis attenuates sepsis-induced acute lung injury.pdf by Yuichi Akama (17892940)

    Published 2025
    “…Our data showed that B-1a cell numbers and frequencies in the pleural and peritoneal cavities were significantly decreased in sepsis. …”
  8. 3488

    Data Sheet 1_A novel molecule targeting neutrophil-mediated B-1a cell trogocytosis attenuates sepsis-induced acute lung injury.pdf by Yuichi Akama (17892940)

    Published 2025
    “…Our data showed that B-1a cell numbers and frequencies in the pleural and peritoneal cavities were significantly decreased in sepsis. …”
  9. 3489
  10. 3490
  11. 3491
  12. 3492

    Data Sheet 1_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx by David Qixiang Chen (8198265)

    Published 2025
    “…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”
  13. 3493

    Data Sheet 2_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx by David Qixiang Chen (8198265)

    Published 2025
    “…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”
  14. 3494

    Data Sheet 3_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx by David Qixiang Chen (8198265)

    Published 2025
    “…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”
  15. 3495
  16. 3496
  17. 3497
  18. 3498
  19. 3499
  20. 3500

    Mice in the NTC and MBC-005 treatment groups were evaluated for bioluminescent signaling at 6-, 13-, and 21-days after tumor inoculation. by Bryan S. Margulies (21492667)

    Published 2025
    “…<p>(A) Malthusian non-linear regression analysis demonstrated that the whole-body bioluminescent signal was significantly different between the different treatment groups (p < 0.0001). …”